Oxybutynin Transdermal Patch — Competitive Intelligence Brief

Oxybutynin Transdermal Patch (Oxybutynin Transdermal Patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Urology / Neurology.

phase 3 Anticholinergic agent M3 muscarinic acetylcholine receptor Urology / Neurology Small molecule

Target snapshot

Oxybutynin Transdermal Patch (Oxybutynin Transdermal Patch) — University of California, Davis. Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxybutynin Transdermal Patch TARGET	Oxybutynin Transdermal Patch	University of California, Davis	phase 3	Anticholinergic agent	M3 muscarinic acetylcholine receptor
Detrol LA	Detrol LA	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic acetylcholine receptors
Albuterol, ipratropium bromide	Albuterol, ipratropium bromide	Children's Hospital of Philadelphia	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor
Indacaterol/glycopyrronium	Indacaterol/glycopyrronium	Orion Corporation, Orion Pharma	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor
Solifenacin succinate treatment	Solifenacin succinate treatment	Barrie Urology Associates	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Drug: ipratropium (AtroventTM)	Drug: ipratropium (AtroventTM)	AstraZeneca	marketed	Anticholinergic bronchodilator	M3 muscarinic acetylcholine receptor
salbutamol + ipratropium bromide nebules	salbutamol + ipratropium bromide nebules	Imperial College London	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class